Skip to content
Bomb Report – Lifestyle
Author:
XORTX Therapeutics Inc.
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
September 18, 2026
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
September 10, 2026
XORTX Announces Director Resignation
July 31, 2026
XORTX Appoints New Director
July 29, 2026
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026
XORTX Meets Nasdaq Continued Listing Requirements
April 21, 2026
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
April 14, 2026
XORTX Announces Results of Annual and Special Meeting of Shareholders
March 27, 2026
XORTX Announces Share Consolidation
March 25, 2026
1
2
Next Page
→